Jamie Justice and Dasatinib
Jamie Justice's geroscience work on clinical biomarkers connects to the D+Q senolytic protocol tested monthly in nonhuman primates for six months.
Nonhuman primates received dasatinib and quercetin once a month for six months.
Jamie Justice is Executive Vice President of the Health Domain at XPRIZE (a technology prize foundation) and an adjunct professor at Wake Forest University School of Medicine. Justice works on biomarkers and clinical trials in geroscience, the study of biological aging mechanisms.
Dasatinib was developed for leukemia as a BCR-ABL tyrosine kinase inhibitor. In geroscience it is studied as a senolytic: a compound that kills senescent cells, which accumulate in tissue and sustain chronic inflammation. The canonical protocol pairs dasatinib with quercetin, abbreviated D+Q, the same combination used in the primate study.
The six-month primate course is a preclinical step before human trials. Justice works on exactly that transition: how to measure whether clearing senescent cells produces a real clinical outcome.
High-confidence edge (0.99) between a prominent geroscience trial designer and the canonical senolytic compound dasatinib, anchored by concrete primate study evidence (D+Q, 6 months, monthly dosing) and mechanistic context that places Justice at the preclinical-to-human-trial boundary her career addresses.